LNP023D
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $82,131 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $82,131 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, TREATMENT OPEN-LABEL, DOSE-BLINDED PARALLEL GROUP, THREE ARM, PROOF-OF-CONCEPT CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN THE TREATMENT OF SUBJECTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY | Novartis Pharmaceuticals Corporation | $82,131 | 0 |
Top Doctors Receiving Payments for LNP023D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Temple, TX | $82,131 | 3 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $82,131
- Total Doctors 0
- Transactions 3
About LNP023D
LNP023D is a drug associated with $82,131 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $82,131 was paid across 3 transactions to 0 doctors.
The most common payment nature for LNP023D is "Unspecified" ($82,131, 100.0% of total).
LNP023D is associated with 1 research study, including "A RANDOMIZED, TREATMENT OPEN-LABEL, DOSE-BLINDED PARALLEL GROUP, THREE ARM, PROOF-OF-CONCEPT CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN THE TREATMENT OF SUBJECTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY" ($82,131).